Engberg J, Aarestrup F M, Taylor D E, Gerner-Smidt P, Nachamkin I
Department of Gastrointestinal Infections, Division of Diagnostics, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
Emerg Infect Dis. 2001 Jan-Feb;7(1):24-34. doi: 10.3201/eid0701.010104.
The incidence of human Campylobacter jejuni and C. coli infections has increased markedly in many parts of the world in the last decade as has the number of quinolone-resistant and, to a lesser extent, macrolide-resistant Campylobacter strains causing infections. We review macrolide and quinolone resistance in Campylobacter and track resistance trends in human clinical isolates in relation to use of these agents in food animals. Susceptibility data suggest that erythromycin and other macrolides should remain the drugs of choice in most regions, with systematic surveillance and control measures maintained, but fluoroquinolones may now be of limited use in the empiric treatment of Campylobacter infections in many regions.
在过去十年中，全球许多地区空肠弯曲菌和结肠弯曲菌感染的发病率显著上升，导致感染的喹诺酮耐药和程度较轻的大环内酯耐药弯曲菌菌株数量也有所增加。我们综述了弯曲菌对大环内酯类和喹诺酮类的耐药情况，并追踪了人类临床分离株的耐药趋势与这些药物在食用动物中的使用情况的关系。药敏数据表明，在大多数地区，红霉素和其他大环内酯类药物仍应作为首选药物，并维持系统的监测和控制措施，但在许多地区，氟喹诺酮类药物目前在弯曲菌感染的经验性治疗中可能用途有限。
